Final Transplant Center-Specific Survival Report · Final 2016 Transplant Center-Specific Survival...

Final 2016 Transplant Center-Specific Survival Report

Introduction The purpose of this report is to provide potential hematopoietic cell transplant (HCT) recipients, their families and the general public with a comparison of survival rates among the centers in the C.W. Bill Young Cell Transplantation Program (the Program) network. Transplant centers may use these reports for quality improvement initiatives. Reporting center-specific survival rates is a requirement of the Stem Cell Therapeutic and Research Act of 2005 (re-authorized in 2010 and 2015), and prior to that, the 1990 Transplant Amendments Act. Because centers vary considerably in the risk level of cases treated, a statistical model was developed to adjust for several risk factors known or suspected to influence outcome. The outcome reported here is one-year overall survival, for recipients of allogeneic HCT in the United States only. No attempts were made to incorporate other outcomes, such as relapse or disease-free survival. The first center-specific risk-adjusted comparisons were published in 19941 and yearly since then. The current report prepared by the Center for International Blood and Marrow Transplant Research (CIBMTR) includes both unrelated and related donor transplants facilitated by the Program between January 1, 2012, and December 31, 2014. The methodology for this analysis has undergone various transformations over the years. The methodology in this report has been used since 2005, thus allowing direct comparisons over the most recent eleven reports. This method adjusts for risk using a censored data logistic regression model2,3,4 that allows inclusion of recipients with incomplete one-year follow-up. Note that although the method has remained the same, the types of patients studied changed with the report generated in 2010 due to inclusion of related donor transplants, which may affect comparisons over time. A risk-adjusted one-year survival rate has been calculated for each center, based on results of the censored data logistic regression. Results will be accessible on the Program website (http://bloodcell.transplant.hrsa.gov/research/transplant_data/us_tx_data/index.html), and a version of this report, as approved by HRSA, will be distributed to HCT centers. This information is available online at www.bethematch.org/access. A total of 179 Program transplant centers are represented in this analysis. Each of these centers performed at least one unrelated or related donor transplant over the three-year window of time from January 1, 2012, to December 31, 2014.

http://bloodcell.transplant.hrsa.gov/research/transplant_data/us_tx_data/index.html

http://www.bethematch.org/access

Final 2016 Transplant Center Specific Survival Report – December 12, 2016 2 of 49

Methods Recipients and data The current analysis includes the three-year time interval from January 1, 2012, to December 31, 2014, for first unrelated or related donor transplants, with follow-up through December 31, 2015. As of the report generated in 2011, a rolling three-year window of transplants is included. This change was based on recommendations from the 2010 Center-Specific Outcomes Analysis Forum5, in order to represent more current transplant center outcomes. This time interval allows for a minimum of one-year follow-up for all eligible cases. All U.S. transplant centers that performed at least one HCT in the time interval were considered for inclusion in the report, provided they had sufficient data with at least one year of follow-up available. A total of 179 U.S. transplant centers are included in this year’s analysis. Of the 23,058 first allogeneic transplants performed by 181 domestic transplant centers in the Program during this time, 18 patients from 2 transplant centers which have closed or are no longer performing HCT were excluded from the analysis*. Thirty-six additional individual patients without any follow-up data were excluded from the remaining centers, leaving a total of 23,004 cases eligible for analysis. Demographics of these cases are given in Table 1, displayed by donor type according to unrelated vs. related donor. Baseline and follow-up data were provided to the CIBMTR by the transplant centers at the time of transplant (baseline), and at 100 days, six months and annually post-transplant, using standardized forms. Race was self-reported by recipients or by the staff at the center. Occasionally, data is not available for significant characteristics for subjects as reported by the centers. If there were sufficient numbers of such subjects, they were included in the multivariate modeling as a distinct category of the covariate. However, when the number of subjects with data not available for a variable is too small (generally less than 20 subjects) to fit the model as its own category (Table 2), those subjects were imputed to the relevant highest frequency category within the variable.

Statistical Analysis Rationale for a fixed effects censored data logistic regression model One of the CIBMTR’s goals for the transplant center-specific outcomes analysis is to calculate a fair and accurate predicted survival rate given a center’s recipient case mix. To do this, we used a fixed effects censored regression model. The fixed-effect logistic regression model provides information about how the recipients actually treated in a particular center would have fared had they been transplanted at a “generic” transplant center within the Program. This model assumes no center effect. In other words, it assumes that recipients are dying at the same uniform rate across all Program transplant centers, after adjusting for covariates. The model also adequately accounts for recipients with incomplete follow-up at one year. Every effort was made to update follow-up information on each recipient. Some recipients are indeed lost to follow-up, and final survival status at one year is unknown. To address this problem, the analysis only includes centers that demonstrated 90% completeness of follow-up, meaning that the one-year status was known for at least 90% of their transplanted recipients. However, there are still some recipients for whom survival status at one year is incomplete 1,664 (7.2%) with less than 12 months of

*These two excluded centers are Texas Oncology (13 patients) and University of Texas Health Science Center (5 patients).


follow-up (although most of them had follow-up done just prior to one year). If these recipients are excluded from the center-specific analysis, it may bias the survival estimates. A censored data version of logistic regression based on pseudo-values proposed by Andersen et al.,2 Klein and Andersen,3 and Klein et al.4 addresses this issue. This method is a generalization of logistic regression that simplifies to logistic regression (on the one-year survival probabilities) when there is no censoring present. This regression technique is used to estimate the fixed effects and predict the recipients’ survival probabilities based on their patient characteristics alone. These predicted survival probabilities are then used to construct confidence limits for a center’s survival probability according to the characteristics of the patients transplanted at that center. The actual survival observed at that center can be compared to these intervals to assess the performance of the center. This method is described in more detail below. Details of fixed effects censored data logistic regression and confidence limits

I. Definition of pseudo-values

To compute the pseudo-value for recipient i, first compute the pooled sample Kaplan-Meier

estimate of survival at one year based on the entire sample, )1(ˆpS . Next compute the Kaplan-Meier

estimate of survival at one year based on the entire dataset with observation i removed )1(ˆ )(i

pS .

The ith pseudo-value is defined by

)1(ˆ)1()1(ˆˆ )(i

ppi SnSn .

If there is no censoring, then the ith pseudo-value is simply the indicator that the ith recipient was alive at one year. These pseudo-values will then be used in a regression model using a logit link, similar to a standard logistic regression model, as described in the next section. The parameters of the regression model can be estimated using generalized estimating equations (GEE), which are implemented in PROC GENMOD in SAS.

II. Model building

Let ( ipi ZZ ,...,1 ) denote the set of covariates in the final model for recipient i . First fit a fixed effects

censored data logistic regression model with no center effect,

p

l

ill

i

ii Z

1

01

ln

.

III. Predicted and observed survival

From the fitted logistic regression model, each recipient has an estimated survival rate

)ˆexp(1

)ˆexp(ˆ

i

iip

based on his or her risk characteristics. The predicted survival rate at center j based on recipient

characteristics )( jSE is the average of the estimated survival rates for all recipients at center j,

jCi

ijn

pSEj

1*ˆ)(

.

The observed one-year survival rate at center j can be computed using the Kaplan-Meier estimate of survival using the recipients at center j. This simplifies to the sample proportion of recipients alive when there is no censoring prior to one year present.


IV. Confidence Limits Confidence limits are generated using a bootstrapping methodology. However, the bootstrap technique was modified slightly from previous years’ reports to improve the coverage probabilities of the intervals, as described in Logan et al.6 Previously, binary outcomes were generated for each individual to simulate the confidence limits; however, a more accurate prediction interval that controls the type I error rate can be obtained by re-sampling the residuals from the general linear model instead. Define the scaled Pearson residual for patient i by

ˆ ˆ

ˆ ˆ(1 )

i ii

i i

pr

p p

,

then the bootstrap re-sampling algorithm to generate a prediction interval for center j is as follows. For b=1 to 10,000:

1. Generate *b

ir for patient i by sampling with replacement from the set of residuals { , 1,..., }ir i n

2. Compute the bootstrap predicted value for patient i as * *ˆ ˆ ˆ(1 )b b

i i i i iY p r p p

3. Compute the predicted center outcome for center j as

* *1

j

b b

j i

i Cj

S Yn

.

Then the 95% predicted confidence bounds for survival at center j are obtained by taking the 2.5th

and 97.5th percentile of*b

jS across the 10,000 bootstrap samples.

This confidence interval refers to the survival rate that might be observed at that center if there were no center effect and those recipients had been transplanted at any center in the network. The observed survival rate can be compared with this confidence interval to see if there is evidence of the center over-performing or under-performing the overall network.

Results Risk factors Based on the recommendation of the 2010 Center-Specific Outcomes Analysis Forum, variables recognized as clinically important were forced into the model regardless of whether they were statistically significant. After careful discussion with clinical and statistical transplant experts, the following essential risk factors were included in the model:

Diagnosis (and disease status/stage) Donor type: matched sibling donor vs. other related vs. unrelated donor Coexisting disease (HCT-specific comorbidity index (HCT-CI), Sorror et al.7) HLA matching8† Recipient age Donor age (unrelated donor marrow or peripheral blood stem cells (PBSC) only) Recipient and donor gender

† For PBSC and marrow transplants, high-resolution typing at HLA-A, -B, -C, and –DRB1 was used for the cases where it was available. For the remaining patients with PBSC and bone marrow graft sources, the best available matching information at HLA-A, -B, -C, and -DRB1 was used. For cord blood transplants, low/intermediate-resolution typing at HLA-A and -B, and high-resolution typing at -DRB1 only were considered.


Recipient cytomegalovirus (CMV) serology Recipient race (self-reported) Recipient Karnofsky/Lansky Performance Status score at transplant Prior autologous transplant Resistant disease (non-Hodgkin lymphoma and Hodgkin lymphoma only) Time from diagnosis to transplant (acute leukemia not in CR1/PIF) Year of transplant

In addition, the following variables were believed to be of uncertain clinical relevance, and so they were included in the model only if statistically significant (p<0.05).

T-cell lineage in acute lymphoblastic leukemia, Philadelphia chromosome in acute lymphoblastic leukemia

NHL subtype Donor parity Donor race Donor CMV serology

The results of the multivariate model are given in Table 2. Significant factors entering this model include:

Recipient age

Recipient race/ethnicity

Karnofsky/Lansky Score at transplant

Prior autologous transplant

Recipient CMV status

Coexisting disease (Sorror HCT-CI)

Disease and disease status/stage

Interval from Dx to Tx (AML and ALL not in CR1/PIF)

Philadelphia chromosome in ALL patients

CLL and other chronic leukemia stage

Sensitivity to chemotherapy (NHL and HL)

NHL subtype‡

Year of transplant

HLA matching by donor and graft type

Donor/Recipient sex match (bone marrow or PBSC only)

Donor age (Unrelated donor bone marrow or PBSC only)

The model is similar to last year, except for the inclusion of Philadelphia chromosome in ALL patients and re-alignment of KPS categories.

‡ NHL subtypes: Indolent B-cell lymphoma includes the following sub-types: Lymphoplasmacytic; splenic marginal zone B-cell; extranodal marginal B-cell of mucosal-associated lymphoid tissue; nodal marginal zone B-cell; grades I, II and III follicle center cell; follicle center cell, grade unknown; Waldenstrom’s macroglobulinemia. Aggressive B-cell lymphoma includes the following sub-types: Diffuse large B-cell including primary mediastinal B-cell lymphoma, Burkitt, and high grade Burkitt-like B-cell. Mantle cell lymphoma includes the following sub-type: Mantle cell lymphoma. Nodal T-cell lymphoma includes the following sub-types: Anaplastic large-cell T/null-cell, primary cutaneous type; peripheral T-cell NOS; angioimmunoblastic T-cell; anaplastic large cell T/null-cell, primary systemic type. Extranodal T-cell lymphoma includes the following sub-types: Extranodal NK/T-cell nasal type; enteropathy-type T-cell; hepatosplenic gamma-delta T-cell; subcutaneous panniculitis-like T-cell; mycosis fungoides; sezary syndrome; large T-cell granular lymphocytic leukemia; aggressive NK-cell leukemia; adult T-cell lymphoma/leukemia. Other B-cell lymphoma. Other T-cell/NK-cell lymphoma.


Center-specific results Final center-specific results are given in Table 3, along with centers’ historical performance. Number of transplanted recipients at each center, actual (observed) survival at one year, predicted survival at one year, 95% confidence intervals for predicted survival, and performance status are displayed for each center. Centers whose actual survival is outside the 95% confidence limits for predicted survival have a “–1” in the performance status column if performing below the confidence limit and a “1” in the performance status column if performing above the confidence limit. Centers with a “0” in the performance status column are performing as predicted. The majority of centers performed as predicted with respect to overall performance in previous years. Since the censored data logistic regression model assumes no center effect, centers with smaller numbers of transplants (e.g. N = 1 or 2) will not have their predicted survival proportion regress toward the network average. Rather, the confidence limits around the predicted survival at that center will simply be much wider than those of larger centers.

Figures 1a–j convey the same data, but via a visual box-plot graphic. Centers are arranged by center number, while reading from left to right across these figures. The actual survival at each center is superimposed with each box plot (using the symbol ‘•’) to give the reader an instantaneous picture of how close to under- or over-performing the center was. The dashed line at 68.9% denotes the overall network survival average, using the Kaplan-Meier estimate of one-year survival from the entire cohort of patients who underwent first allogeneic HCT in 2012-2014. Comparison of last 10-year center-specific report results Since the censored data logistic regression model has been used consistently since the 2005 analysis, centers’ performance results among the last 10 reports can be compared, covering transplants performed in 2001–2005 for the 2007 report, to those performed in 2012–2014 for the 2016 report. Note that the 2007 analysis and the 2016 analysis involve completely non-overlapping patients. Table 4 shows the total number of centers, and the number of over-performing and under-performing centers for each analysis. A total of 23 centers were identified as under-performing in the 2016 analysis, while 17 centers were identified as over-performing in the 2016 analysis. Table 5 lists those centers that were either under-performing (–1), or over-performing (1), in any analysis between 2007 and 2016. If the center performed within predicted confidence limits for one of those years a “0” is displayed in the cell. Centers not listed in Table 5 were within their predicted confidence limits for all years for which they were included in the analysis. Of the 23 centers that were identified as under-performing in the 2016 analysis, 16 were also identified as under-performing in the 2015 analysis and no centers were identified as under-performing in each of the past 10 analyses. Eleven of the 17 centers identified as over-performing in the 2016 analysis were also over-performing in the 2015 analysis. Only one center was over-performing in each of the past 10 analyses.


Summary A censored data logistic regression model has been fitted to survival data for first unrelated and related donor hematopoietic cell transplants at U.S. centers from January 1, 2012 through December 31, 2014. Overall survival (unadjusted) at one year for all first unrelated and related donor transplants during the time period covered by this report was 68.9% (95% CI 68.3-69.5%). During this time period, the one-year overall survival for recipients of first unrelated donor transplants was 66.3% (95% CI 65.5-67.1%); that for first related recipients was 72.5% (95% CI 71.6-73.4%). Overall survival for individual years 2012-2014 is shown in Table 6. The model is adjusted for recipient age, recipient race/ethnicity; Karnofsky/Lansky score, prior autologous transplant, recipient CMV status, coexisting disease (Sorror HCT-CI), disease/stage, Philadelphia positive-status in ALL, CLL and other chronic leukemia stage, interval from diagnosis to transplant (ALL and AML not in CR1/PIF only), NHL subtype, sensitivity to chemotherapy (NHL and HL), year of transplant, donor type/graft type/HLA matching, BM or PBSC donor/recipient sex match, and BM or PBSC donor age at transplant. This report helps identify centers that may have under-performed or over-performed compared to the overall network of transplant centers during this specified time period. A total of 23 centers were identified as under-performing compared to an average transplant center in the network, and 17 centers were identified as over-performing compared to an average transplant center in the network.


References

1. National Marrow Donor Program Center-Specific Report. Internal NMDP Report, 1998. 2. Andersen PK, Klein JP and Rosthoj S. (2003). Generalized linear models or correlated

pseudo-observations with applications to multi-state models. Biometrika, 90: 15-27. 3. Klein JP and Andersen PK. (2005) Regression modeling of competing risks data based on

pseudo-values of the cumulative incidence function. Biometrics, 61: 223-229. 4. Klein JP, Logan BR, Harhoff M and Andersen PK. (2007) Analyzing survival curves at a fixed

point in time. Statistics in Medicine, 26: 4505-4519. 5. Recommendations from the 2010 Center-Specific Outcomes Analysis Forum can be found at

http://www.cibmtr.org/Meetings/Materials/CSOAForum/Documents/Center_Forum_Summary2010.pdf.

6. Logan BR, Nelson G and Klein JP. (2008). Analyzing center-specific outcomes in hematopoietic cell transplantation. Lifetime Data Analysis, 14: 389-404.

7. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. (2005). Hematopoietic Cell Transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106(8):2912-2919.

8. Weisdorf D, Spellman S, Haagenson M, et al. (2008). Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant, 14:748-758.


Table 1. Characteristics of First Allogeneic Transplant Recipients (2012-2014)

Related Unrelated

Variable N (%) N (%)

Number of recipients 9480 13524

Number of transplant centers 177 152

Recipient sex

Male 5559 (59) 7929 (59)

Female 3921 (41) 5595 (41)

Recipient age at transplant

0 to 9 751 (8) 1478 (11)

10 to 19 749 (8) 1053 (8)

20 to 29 815 (9) 1143 (8)

30 to 39 830 (9) 1264 (9)

40 to 49 1360 (14) 1670 (12)

50 to 59 2606 (27) 2858 (21)

60 to 64 1283 (14) 1871 (14)

65 to 69 811 (9) 1586 (12)

70 or older 275 (3) 601 (4)

Median (Range) 51 (0-82) 50 (0-83)


Caucasian 6339 (67) 10486 (78)

Hispanic1 1060 (11) 1143 (8)

Black/African American 1080 (11) 869 (6)

Asian/Pacific Islander 488 (5) 526 (4)

American Indian/Alaska Native 48 (1) 69 (1)

Other/multiple race 212 (2) 198 (1)

Decline/unknown 253 (3) 233 (2)


10 to 60 151 (2) 197 (1)

70 to 100 9136 (96) 13150 (97)

Unknown 193 (2) 177 (1)


No 8542 (90) 12368 (91)

Yes 938 (10) 1156 (9)

Recipient CMV status

Negative 3383 (36) 5177 (38)

Positive 5984 (63) 8240 (61)

Unknown/Inconclusive 113 (1) 107 (1)


Table 1. Continued.

Related Unrelated


History of malignancy2

Absent 8531 (90) 11950 (88)

Present 949 (10) 1573 (12)

Unknown 0 1 (<1)

Sorror HCT-CI

0 3250 (34) 4352 (32)

1 1331 (14) 1863 (14)

2 1297 (14) 1954 (14)

3 1610 (17) 2177 (16)

4 863 (9) 1425 (11)

≥ 5 1093 (12) 1712 (13)

Unknown 36 N/A 41 N/A

Broad disease

Acute Myelogenous Leukemia (AML) 3164 (33) 5020 (37)

Acute Lymphoblastic Leukemia (ALL) 1363 (14) 1865 (14)

Other Acute Leukemia 111 (1) 148 (1)

Chronic Myelogenous Leukemia (CML) 327 (3) 411 (3)

Chronic Lymphocytic Leukemia (CLL) and Other Chronic Leukemia

301 (3) 429 (3)

Myelodysplastic Disorders (MDS) 1121 (12) 1903 (14)

Myeloproliferative Diseases 278 (3) 452 (3)

Non-Hodgkin Lymphoma (NHL) 1142 (12) 1314 (10)

Hodgkin Lymphoma (HL) 292 (3) 336 (2)

Plasma Cell Disorders 322 (3) 254 (2)

Solid Tumors 28 (<1) 11 (<1)

Severe Aplastic Anemia 385 (4) 384 (3)

Inherited Erythrocyte Abnormalities 383 (4) 299 (2)

Inherited Immune System Disorders 166 (2) 343 (3)

Inherited Metabolism Disorders 22 (<1) 166 (1)

Histiocytic Disorders 44 (<1) 139 (1)

Inherited Platelet Abnormalities 6 (<1) 12 (<1)

Other Nonmalignant Diseases 25 (<1) 38 (<1)

Disease-Stage

AML-1st CR 1889 (20) 2877 (21)

AML-2nd CR 505 (5) 972 (7)

AML-3rd or higher CR/relapse/PIF 747 (8) 1125 (8)

AML-Unknown stage 23 (<1) 46 (<1)

ALL-1st CR 864 (9) 1107 (8)

ALL-2nd CR 321 (3) 509 (4)


Table 1. Continued.

Related Unrelated


ALL-3rd or higher CR/relapse/PIF 160 (2) 199 (1)

ALL-Unknown stage 18 (<1) 50 (<1)

Other Acute Leukemia 111 (1) 148 (1)

CML-Early3 86 (1) 121 (1)

CML-Intermediate I3 149 (2) 164 (1)

CML-Intermediate II3 19 (<1) 26 (<1)

CML-Advanced3 21 (<1) 27 (<1)

CML-Unknown Stage3 52 (1) 73 (1)

CLL 255 (3) 353 (3)

PLL and Other Chronic Leukemia 46 (<1) 76 (1)

MDS-RA/RARS/RCMD/RCMDRS/5Q 263 (3) 410 (3)

MDS-RAEB1/RAEB2/CMML 595 (6) 1044 (8)

MDS-Other 263 (3) 449 (3)

Myeloproliferative Diseases 278 (3) 452 (3)

NHL-Indolent B-cell4 196 (2) 233 (2)

NHL-Aggressive B-cell4 434 (5) 462 (3)

NHL-Mantle cell4 124 (1) 187 (1)

NHL-Nodal T-cell4 191 (2) 199 (1)

NHL-Extranodal T-cell4 128 (1) 149 (1)

NHL-Other B-cell4 49 (1) 57 (<1)

NHL-Other T-cell/NK-cell4 20 (<1) 27 (<1)

Hodgkin Lymphoma 292 (3) 336 (2)

Plasma Cell Disorders 322 (3) 254 (2)

Solid Tumors 28 (<1) 11 (<1)

Severe Aplastic Anemia 385 (4) 384 (3)

Fanconi Anemia 21 (<1) 86 (1)

Other Inherited Erythrocyte Abnormalities 362 (4) 213 (2)

Inherited Immune System Disorders 166 (2) 343 (3)

Inherited Metabolism Disorders 22 (<1) 166 (1)

Histiocytic Disorders 44 (<1) 139 (1)

Other Nonmalignant Diseases 31 (<1) 50 (<1)

Interval from Dx to Tx (AML and ALL not in CR1/PIF)

1st CR or PIF 3279 (72) 4740 (69)

Other stage, Dx to Tx ≤ 18 months 617 (14) 999 (15)

Other stage, Dx to Tx > 18 months 598 (13) 1067 (15)

Unknown stage 33 (1) 79 (1)


Table 1. Continued.

Related Unrelated


ALL T-cell lineage

Non T-cell lineage 1121 (82) 1460 (78)

T-cell lineage 183 (13) 331 (18)

Unknown 59 (4) 74 (4)

ALL Philadelphia chromosome

Ph-negative 942 (69) 1337 (72)

Ph-positive 363 (27) 458 (25)

Unknown 58 (4) 70 (4)

CLL, PLL, and other chronic leukemia stage

CR/nPR/PR 209 (69) 276 (64)

NR/SD 50 (17) 86 (20)

Progression/Relapse 33 (11) 50 (12)

Unknown 9 (3) 17 (4)

NHL chemotherapy sensitivity

Resistant 186 (16) 194 (15)

Sensitive 941 (82) 1100 (84)

Untreated/Unknown 15 (1) 20 (2)

HL chemotherapy sensitivity

Resistant 52 (18) 60 (18)

Sensitive 238 (82) 272 (81)

Untreated/Unknown 2 (1) 4 (1)

Year of transplant

2012 3036 (32) 4248 (31)

2013 3182 (34) 4675 (35)

2014 3262 (34) 4601 (34)

Product type

Bone marrow 2358 (25) 2753 (20)

PBSC ± Bone marrow 7067 (75) 8557 (63)

Cord blood ± Others 55 (1) 2214 (16)

Product type - Details

Bone marrow 2358 (25) 2753 (20)

PBSC 7059 (74) 8551 (63)

PBSC + Bone marrow 8 (<1) 6 (<1)

Single-cord blood 25 (<1) 808 (6)

Single-cord blood + Bone marrow 25 (<1) 0

Single-cord blood + PBSC 1 (<1) 102 (1)

Multiple-cord blood 1 (<1) 1229 (9)

Multiple-cord blood + Bone marrow 3 (<1) 0


Table 1. Continued.

Related Unrelated


Multiple-cord blood + PBSC 0 75 (1)

TBI

No TBI 6267 (66) 9115 (67)

TBI+Cy ± Other 2190 (23) 2988 (22)

TBI ± Other 1023 (11) 1421 (11)

CIBMTR categorized preparative regimen intensity (intended dose)

Myeloablative 4978 (53) 7476 (55)

Non-myeloablative / Reduced intensity (RIC) 4489 (47) 6028 (45)

Not Specified 13 (<1) 20 (<1)

Conditioning regimen drugs

Bu+Cy ± Other 1354 (14) 1741 (13)

Bu+Mel ± Other 98 (1) 197 (1)

Bu+Thio ± Other 14 (<1) 36 (<1)

Bu+Flud ± Other 2416 (25) 4188 (31)

Bu ± Other 144 (2) 185 (1)

Flud+Mel ± Other 1517 (16) 2449 (18)

Flud+Cy ± Other 1298 (14) 1717 (13)

Flud ± Other 516 (5) 729 (5)

Mel+Thio ± Other 9 (<1) 20 (<1)

Cy+Thio ± Other 113 (1) 187 (1)

Treo ± Other 1 (<1) 0

BEAM 79 (1) 65 (<1)

CBV 13 (<1) 12 (<1)

Mel ± Other 103 (1) 114 (1)

Cy ± Other 1310 (14) 1442 (11)

Other 495 (5) 442 (3)

Unrelated BM or PBSC donor HLA match5

8/8 allele level 8631 (76)

7/8 allele level 2000 (18)

≤ 6/8 Allele level 80 (1)

Well-matched6 402 (4)

Partially-matched6 168 (1)

Mismatched6 18 (<1)

Unknown 11 (<1)


Table 1. Continued.

Related Unrelated


Unrelated single-cord blood HLA match7

6/6 182 (20)

5/6 491 (54)

≤ 4/6 235 (26)

Unknown 2 (<1)

Unrelated multiple-cord blood HLA match8

6/6 53 (4)

5/6 477 (37)

≤ 4/6 758 (58)

Unknown 16 (1)

Related donor type

Syngeneic 104 (1)

Matched sibling 7436 (78)

Matched relative 369 (4)

One locus mismatched relative 164 (2)

> One locus mismatched relative 1332 (14)

Mismatched relative, unknown match grade 17 (<1)

Related Cord Blood 55 (1)

Matched, unknown relationship 2 (<1)

Mismatched, unknown relationship 1 (<1)

BM or PBSC donor sex

Male 4994 (53) 7709 (68)

Female 4431 (47) 3587 (32)

Unknown 0 14 (<1)

BM or PBSC donor/recipient sex match

Male/Male 3061 (32) 4891 (43)

Male/Female 1933 (21) 2818 (25)

Female/Male 2467 (26) 1791 (16)

Female/Female 1964 (21) 1796 (16)

Unknown 0 14 (<1)

Unrelated BM or PBSC donor age at tx

Under 30 6190 (55)

30 to 39 2564 (23)

40 to 49 1521 (13)

50 or older 566 (5)

Unknown 469 (4)

Median (Range) 28 (17-62)


1 Hispanic ethnicity reported with Caucasian race or Hispanic race, are classified as Hispanic. 2 Excludes non-melanoma skin cancer. 3 CML disease categories: Early includes: hematologic CR1; hematologic CR2+ from CP. Intermediate I includes: CP1; CP2+

with either cytogenetic or molecular CR; hematologic CR2+ from either AP or BP. Intermediate II includes: CP2+ without cytogenetic or molecular CR; AP. Advanced includes: BP.

4 NHL subtypes: Indolent B-cell lymphoma includes the following sub-types: Lymphoplasmacytic; splenic marginal zone B-cell; extranodal marginal B-cell of mucosal-associated lymphoid tissue; nodal marginal zone B-cell; grades I, II and III follicle center cell; follicle center cell, grade unknown; Waldenstrom’s macroglobulinemia. Aggressive B-cell lymphoma includes the following sub-types: Diffuse large B-cell including primary mediastinal B-cell lymphoma, Burkitt, and high grade Burkitt-like B-cell. Mantle cell lymphoma includes the following sub-type: Mantle cell lymphoma. Nodal T-cell lymphoma includes the following sub-types: Anaplastic large-cell T/null-cell, primary cutaneous type; peripheral T-cell NOS; angioimmunoblastic T-cell; anaplastic large cell T/null-cell, primary systemic type. Extranodal T-cell lymphoma includes the following sub-types: Extranodal NK/T-cell nasal type; enteropathy-type T-cell; hepatosplenic gamma-delta T-cell; subcutaneous panniculitis-like T-cell; mycosis fungoides; sezary syndrome; large T-cell granular lymphocytic leukemia; aggressive NK-cell leukemia; adult T-cell lymphoma/leukemia. Other B-cell lymphoma. Other T-cell/NK-cell lymphoma.

5 Allele level typing or best available typing at HLA-A, -B, -C, -DRB1. 6 Full allele level typing not available. 7 Antigen level at HLA-A, -B; allele level at HLA-DRB1. 8 The match grade of the worst-matched unit.

Table 1. Continued.

Related Unrelated


Unrelated BM or PBSC donor race/ethnicity

Caucasian 6654 (59)

Hispanic1 610 (5)

Black/African American 356 (3)

Asian/Pacific Islander 271 (2)

American Indian/Alaska Native 68 (1)

Other/Multiple Race 596 (5)

Decline/Unknown 2755 (24)

BM or PBSC donor CMV status

Negative 4498 (48) 6784 (60)

Positive 4910 (52) 4522 (40)

Unknown/Inconclusive 17 (<1) 4 (<1)

BM or PBSC donor parity

0 540 (6) 1949 (17)

≥ 1 1074 (11) 1317 (12)

Male 5012 (53) 7767 (69)

Unknown 2799 (30) 277 (2)

Recipient Consent

Recipient Unconsented 852 (9) 589 (4)

Recipient Consented 8628 (91) 12935 (96)


Table 2: Results of multivariate pseudovalue logistic regression model for 1-year survival

Variable n OR (95% CI) p-value

Recipient age at transplant

<0.001

0 to 9 2229 1.00

10 to 19 1802 0.95 (0.79-1.14) 0.597

20 to 29 1958 1.04 (0.86-1.25) 0.691

30 to 39 2094 0.90 (0.75-1.09) 0.279

40 to 49 3030 0.79 (0.66-0.94) 0.007

50 to 59 5464 0.62 (0.52-0.73) <0.001

60 to 64 3154 0.63 (0.53-0.76) <0.001

65 to 69 2397 0.55 (0.46-0.66) <0.001

70 or older 876 0.50 (0.41-0.62) <0.001


0.011

Caucasian 16825 1.00

Hispanic 2203 1.01 (0.91-1.13) 0.811

Black/African American 1949 0.80 (0.71-0.90) <0.001

Asian/Pacific Islander 1014 1.07 (0.92-1.26) 0.373

American Indian/Alaska Native 117 0.89 (0.58-1.36) 0.592

Other/multiple race 410 1.06 (0.83-1.34) 0.653

Decline/unknown 486 1.02 (0.81-1.27) 0.892


<0.001

70 to 100 22286 1.00

10 to 60 348 0.37 (0.29-0.47) <0.001

Unknown 370 0.90 (0.71-1.13) 0.363

Sorror HCT-CI <0.001

0 7602 1.00

1 3194 0.88 (0.80-0.98) 0.016

2 3251 0.78 (0.71-0.87) <0.001

3 3787 0.71 (0.64-0.78) <0.001

4 2288 0.65 (0.58-0.72) <0.001

≥ 5 2805 0.46 (0.42-0.51) <0.001

Unknown 77 0.99 (0.58-1.68) 0.958

Recipient CMV <0.001

Negative 8560 1.00

Positive 14224 0.78 (0.73-0.83) <0.001

Unknown 220 0.86 (0.62-1.19) 0.354

Disease/stage <0.001

AML-1st CR1 4832 1.00

AML-2nd CR 1477 0.70 (0.61-0.82) <0.001

AML-3rd or higher CR/relapse/PIF1 1875 0.39 (0.35-0.44) <0.001

ALL-1st CR1 2039 1.19 (1.03-1.38) 0.020

ALL-2nd CR 830 0.47 (0.38-0.58) <0.001


Table 2. Continued.


ALL-3rd or higher CR/relapse/PIF 359 0.38 (0.30-0.49) <0.001

Other acute leukemia 259 1.19 (0.88-1.62) 0.258

CML-Early2 207 1.14 (0.82-1.59) 0.447

CML-Intermediate I2 313 1.05 (0.81-1.37) 0.704

CML-Intermediate II2 45 0.53 (0.29-0.98) 0.045

CML-Advanced2 48 0.31 (0.17-0.57) <0.001

CML-Unknown 125 0.81 (0.55-1.20) 0.295

Chronic lymphocytic leukemia 608 1.88 (1.45-2.43) <0.001

PLL and other chronic leukemia 122 0.78 (0.53-1.14) 0.198

MDS-RA/RARS/RCMD/RCMDRS/5q 673 1.03 (0.86-1.24) 0.717

MDS-RAEB1/RAEB2/CMML 1639 0.80 (0.71-0.91) 0.001

MDS-Other 712 0.90 (0.76-1.07) 0.237

Myeloproliferative diseases 730 1.20 (1.00-1.44) 0.047

Non-Hodgkin lymphoma 2456 2.03 (1.54-2.66) <0.001

Hodgkin lymphoma 628 1.70 (1.28-2.24) 0.000

Plasma cell disorders 576 0.78 (0.62-0.97) 0.028

Solid tumors 39 0.30 (0.15-0.58) 0.000

Severe aplastic anemia 769 1.94 (1.53-2.46) <0.001

Fanconi anemia 107 1.25 (0.75-2.09) 0.391

Other inherited erythrocyte abnormalities 575 3.60 (2.56-5.08) <0.001

Inherited immune system disorders 509 1.92 (1.42-2.58) <0.001

Inherited metabolism disorders 188 1.10 (0.74-1.64) 0.627

Histiocytic disorders 183 1.09 (0.75-1.57) 0.654

Other nonmalignant disease 81 0.72 (0.45-1.16) 0.176

ALL Philadelphia chromosome <0.001

Ph-Negative 2279 1.00

Ph-Positive 821 1.38 (1.12-1.70) 0.002

Unknown 128 0.65 (0.44-0.94) 0.024

CLL, PLL, and other chronic leukemia stage <0.001

CR/nPR/PR/Untreated1 511 1.00

NR/SD 136 0.50 (0.32-0.77) 0.002

Progression/Relapse 83 0.38 (0.23-0.62) <0.001

Interval from Dx to Tx (AML and ALL not in CR1/PIF) <0.001

≤ 18 months 1616 1.00

> 18 months 1665 1.86 (1.60-2.17) <0.001

NHL subtype3 <0.001

Indolent B-cell 429 1.00

Aggressive B-cell 896 0.43 (0.32-0.58) <0.001

Mantle cell 311 0.53 (0.37-0.76) <0.001

Nodal T-cell 390 0.78 (0.54-1.11) 0.164


Table 2. Continued.


Extranodal T-cell 277 0.41 (0.29-0.60) <0.001

Other B-cell 106 0.42 (0.25-0.68) <0.001

Other T-cell/NK-cell 47 0.30 (0.15-0.58) <0.001

Sensitivity to chemotherapy (NHL) <0.001

Sensitive1 2076 1.00

Resistant 380 0.49 (0.39-0.62) <0.001

Sensitivity to chemotherapy (HL) 0.038

Sensitive1 516 1.00

Resistant 112 0.59 (0.36-0.97) 0.039


0.262

No 20910 1.00

Yes 2094 0.92 (0.80-1.06) 0.262

Year of transplant 0.219

2012 7284 1.00

2013 7857 1.04 (0.96-1.12) 0.337

2014 7863 1.07 (0.99-1.15) 0.082

Donor type/graft type/HLA4 <0.001

Matched sibling 7438 1.00

Syngeneic twins 104 2.65 (1.43-4.90) 0.002

Matched relative 369 0.93 (0.72-1.19) 0.541

One mismatch relative 164 0.79 (0.55-1.12) 0.184

≥ 2 mismatch relative 1350 0.75 (0.66-0.86) <0.001

URD 8/8 8642 0.93 (0.85-1.01) 0.084

URD 7/8 2000 0.64 (0.56-0.72) <0.001

URD ≤ 6/8 and URD mismatched5 98 0.54 (0.35-0.83) 0.005

URD well matched5 402 0.83 (0.66-1.05) 0.117

URD partially matched5 168 0.69 (0.49-0.96) 0.030

Unrelated single UCB 6/6 182 0.80 (0.52-1.22) 0.293

Unrelated single UCB 5/6 493 0.40 (0.32-0.51) <0.001

Unrelated single UCB ≤ 4/6 235 0.43 (0.32-0.59) <0.001

Unrelated multiple UCB 6/66 53 0.52 (0.29-0.95) 0.034

Unrelated multiple UCB 5/66 477 0.45 (0.37-0.56) <0.001

Unrelated multiple UCB ≤ 4/66 774 0.39 (0.33-0.47) <0.001

Related CB 55 1.18 (0.42-3.37) 0.754

BM or PBSC donor/recipient sex match <0.001

Female/Female 3760 1.00

Female/Male 4258 0.78 (0.71-0.87) <0.001

Male/Female1 4757 0.95 (0.85-1.05) 0.286

Male/Male1 7960 0.92 (0.84-1.01) 0.080


Table 2. Continued.


BM or PBSC donor age at transplant <0.001

18 to 291 6190 1.00

30 to 39 2564 0.89 (0.80-0.99) 0.034

40 to 49 1521 0.73 (0.65-0.83) <0.001

50 to 59 566 0.65 (0.53-0.78) <0.001

Unknown 469 0.91 (0.73-1.13) 0.407 OR indicates odds ratio; CI indicates confidence interval 1 Includes imputed data from a small number of patients with missing data for this covariate. 2 CML disease categories: Early includes: hematologic CR1; hematologic CR2+ from CP. Intermediate I includes: CP1; CP2+

with either cytogenetic or molecular CR; hematologic CR2+ from either AP or BP. Intermediate II includes: CP2+ without cytogenetic or molecular CR; AP. Advanced includes: BP.

3 NHL subtypes: Indolent B-cell lymphoma includes the following sub-types: Lymphoplasmacytic; splenic marginal zone B-cell; extranodal marginal B-cell of mucosal-associated lymphoid tissue; nodal marginal zone B-cell; grades I, II and III follicle center cell; follicle center cell, grade unknown; Waldenstrom’s macroglobulinemia. Aggressive B-cell lymphoma includes the following sub-types: Diffuse large B-cell including primary mediastinal B-cell lymphoma, Burkitt, and high grade Burkitt-like B-cell. Mantle cell lymphoma includes the following sub-type: Mantle cell lymphoma. Nodal T-cell lymphoma includes the following sub-types: Anaplastic large-cell T/null-cell, primary cutaneous type; peripheral T-cell NOS; angioimmunoblastic T-cell; anaplastic large cell T/null-cell, primary systemic type. Extranodal T-cell lymphoma includes the following sub-types: Extranodal NK/T-cell nasal type; enteropathy-type T-cell; hepatosplenic gamma-delta T-cell; subcutaneous panniculitis-like T-cell; mycosis fungoides; sezary syndrome; large T-cell granular lymphocytic leukemia; aggressive NK-cell leukemia; adult T-cell lymphoma/leukemia. Other B-cell lymphoma. Other T-cell/NK-cell lymphoma.

4 Transplants using a related donor UCB graft source are included in the most appropriate HLA type category for related donors.

5 Full allele level typing not available. 6 The match grade of the worst-matched unit.


Table 3. Center-Specific Results

Survival 95% Conf. Int. Performance by report year1,2

Center Code Center Name n

Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

1 Rady Children's Hospital San Diego

43 86.0 79.1 67.1 90.6 0 0 0 0 0 0 0 0 0 0

2 Cancer Institute of New Jersey

100 60.0 66.6 57.7 75.3 0 0 0 0 0 0 0 0 0 0

3 Avera McKennan Transplant Institute

40 45.0 64.5 49.9 77.9 0 0 0 0 -1 -1 -1 -1 -1 -1

4 Nationwide Children's Hospital

66 84.8 81.6 72.6 90.4 0 0 0 0 0 0 0 0 0 0

5 Loma Linda University Cancer Center

23 91.3 77.0 59.8 92.9 1 1 1 1 0 0 0 0 0 0

6 Mayo Clinic Florida - Jacksonville

80 52.5 63.0 53.1 73.2

0 0

0 0 0 0 -1 -1

7 BMT Program of Mayo Clinic/ Nemours and Wolfson Children's Hospital

16 62.5 74.3 52.9 93.1

0 0 -1 -1 0 0 0 0

8

NIH - NCI Experimental Transplantation and Immunology Branch (Related Donor Program)

73 73.9 72.8 63.2 82.5

0

0 0 0 0 0 0

9 Latter Day Saints Hospital 140 64.0 64.3 56.7 72.2

0 0 0 0 0 0 0 0 0

10 University of North Carolina Hospitals - Chapel Hill

194 64.9 70.0 64.1 76.2 0 0 0 0 1 0 0 0 0 0

11 Jewish Hospital Blood and Marrow Transplant Center

101 71.2 70.4 61.9 79.1 0 0 0 0 0 0 0 0 0 0

12 University of Alabama Birmingham

202 61.3 68.1 62.2 74.3 0 0 0 0 0 0 0 -1 -1 -1

13 Oregon Health and Science University

242 65.4 63.6 57.9 69.4 0 0 0 0 0 0 0 0 0 0


Table 3. Continued.

Survival 95 Conf. Int. Performance by report year1,2


Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

14 Ann & Robert H. Lurie Children's Hospital of Chicago

71 77.5 80.9 71.8 89.6 0 0 0 0 1 0 0 0 0 0

15 Christiana Care 24 79.2 72.0 54.4 88.1 -1 -1 0 0 0 0 0 0 0 0

16 Hackensack University Medical Center

422 65.6 65.0 60.9 69.4 0 0 0 0 . 0 0 0 0 0

17 Fox Chase Temple University Hospital Bone Marrow Transplant Program

68 69.1 65.5 54.5 76.1 0 0 0 0 -1 0 -1 0 0 0

18 Texas Transplant Institute 214 61.5 65.0 59.2 71.0 0 0 0 0 0 0 0 0 -1 0

19 Children's Medical Center - Dallas

71 70.4 80.7 71.7 89.4 -1 -1 -1 0 0 0 0 -1 -1 -1

20 Medical City Dallas Hospital 106 67.6 66.9 58.3 75.4 0 0 0 0 0 0 0 0 0 0

21 Louisiana State University Health Sciences Center- Shreveport

2 100.0 79.2 16.7 100.0

0

0 0 0 0 0

22 Loyola University Medical Center

166 61.7 62.5 55.6 69.5

0 -1 0 0 0 0

23 The Children's Hospital of Denver

76 76.3 74.1 64.8 83.5 0 0 0 1 1 1 0 0 0 0

24 Colorado Blood Cancer Institute

291 67.3 68.5 63.6 73.5 0 0 0 0 0 0 0 0 0 0

25 Baylor College of Medicine 255 78.7 72.4 67.4 77.7 0 0 0 0 0 0 1 1 0 1

26 Osborn Hematopoietic Malignancy & Transplantation Program

106 66.7 65.9 57.4 74.6 0 0 0 0 0 0 0 0 0 0

27 University of Maryland School of Medicine

115 65.9 70.9 62.9 79.3 0 0 -1 -1 0 0 0 0 0 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

28 UMass Memorial Medical Center

84 63.0 59.7 49.7 69.7 0 0 0 0 0 0 0 0 0 0

29 University of Mississippi Medical Center - Jackson

69 51.9 70.3 59.9 80.2 -1 0 0 0 -1 -1 0 -1 -1 -1

30 University of California, San Diego Medical Center

144 65.9 67.6 60.2 75.1 0 0 0 0 0 0 0 0 0 0

31 Cardinal Glennon Children's Hospital

12 91.7 80.4 57.0 100.0 0 0 0 0 0 0 0 0 0 0

32 Thomas Jefferson University 133 68.2 64.3 56.7 72.3 -1 -1 -1 -1 0 0 0 0 0 0

33 Abramson Cancer Center University - Pennsylvania Medical Center

256 65.5 57.0 51.5 62.9 0 0 0

-1 -1 -1 1 1 1

34 Children's Healthcare of Atlanta at Egleston

103 80.5 80.4 73.0 87.7 0 0 0 0 0 0 0 1 1 0

35 University of Illinois at Chicago Medical Center

67 72.7 73.0 63.2 82.8

0 0 0 0 0 0 0

36 Henry Ford Hospital Bone Marrow Transplant Program

69 68.1 64.7 54.0 75.1 0 0 0 0 0 0 0 0 0 0

37 The Blood and Marrow Transplant Program at Northside Hospital

239 76.6 64.1 58.4 70.0 0 0 1 1 1 1 1 1 1 1

38 Indiana Blood & Marrow Transplantation

76 66.8 72.6 62.7 82.4 0 0 0 0 0 0 0 0 0 0

39 Nicklaus Children's Hospital 29 72.4 75.5 60.1 89.6 0 0 0 0 0 -1 0 0 0 0

40 Louisiana State University Children's Hospital

23 52.2 77.5 60.8 92.8 0 0 0 0 0 0 -1 -1 0 -1

41 Penn State Hershey Medical Center

197 61.2 70.3 64.2 76.7 0 0 0 0 0 -1 -1 -1 -1 -1


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

42 Helen DeVos Children's Hospital

18 72.2 75.7 55.6 93.9 0 0 0 0 0 0 0 0 0 0

43 Northwestern Memorial Hospital

230 65.8 64.8 59.1 70.9 0 0 0

-1 0 0 0 0

44 University of California-Davis Cancer Center

84 66.6 74.1 64.9 83.0 0 0 0 0 0 0 0 0 0 0

45 Tulane University Medical Center

30 70.0 71.7 55.8 86.8 0 0 0 0 -1 0 0 0 0 0

46 UT Southwestern Medical Center - BMT Program

76 69.7 71.5 61.7 81.2 0 0 0 0 0 0 0 0 0 0

47 Beth Israel Deaconess Medical Center

77 74.0 64.2 54.0 74.2 0 0 0 0 0 0 0 0 1 0

48 University of Miami - Adults 123 66.4 64.1 56.0 72.2 0 0 0 0 0 0 0 0 0 0

49 New York Presbyterian Hospital

270 53.1 57.3 51.9 62.8 0 0 0 0 0 0 0 0 0 0

50 Cedars-Sinai Medical Center 137 57.4 68.3 60.8 76.1 0 0 -1 -1 -1 -1 -1 -1 -1 -1

51 Morgan Stanley Children's Hospital of New York

52 84.6 83.5 73.8 92.9 0 0 0 0 0 0 0 0 0 0

52 UCSF Benioff Children's Hospital - Oakland

29 82.3 80.2 66.1 93.4 0 0 0 0 0 -1 0 0 0 0

53 Fairfax-Northern Virginia Hospital

19 46.3 68.1 46.9 87.3 0 0 0 0 -1 -1 -1 -1 -1 -1

54 Steven and Alexandra Cohen Children's Medical Center of New York

40 70.0 81.6 69.7 92.6 0 0 0 0 0 0 0 0 0 0

55 Alfred I. duPont Hospital for Children

30 80.0 76.8 61.9 90.8

0 0 0 0 0 0 0

56 Texas Tech University Medical Center

4 100.0 81.2 39.8 100.0 0 0 0 0 0 0 -1 -1 0 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

57 Scripps Blood & Marrow Transplant Program

42 54.8 62.5 48.5 76.4 0 0 0 0 0 0 0 0 0 0

58 Charleston Hematology Oncology

7 53.6 68.7 32.4 98.3

0 -1 -1 0 0 0 0

59 Fred Hutchinson Cancer Center

747 75.2 69.9 67.0 73.2 1 1 0 0 0 0 1 1 1 1

60 Shands HealthCare & University of Florida

121 71.8 66.1 57.8 74.2 0 0 0 0 -1 0 0 1 1 0

61 University of Iowa Hospital & Clinics

145 73.8 63.0 55.7 70.7 0 0 0 0 -1 0 0 1 1 1

62 University of Kentucky Medical Center

91 63.4 69.2 60.2 78.3 0 0 0 0 0 0 0 0 0 0

63 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

564 72.0 72.3 68.9 76.1 0 0 0

1 1 1 0 0 0

64 Cleveland Clinic 221 64.5 69.0 63.4 75.2 0 0 0 0 0 0 0 -1 0 0

65 The Ohio State University Medical Center

330 68.8 68.2 63.6 73.3 0 0 0 0 0 0 0 0 0 0

66 Hahnemann University Hospitals

5 60.0 69.0 26.8 100.0

0 0

67 University of Pittsburgh Medical Center

109 62.4 66.5 57.9 75.1 0 0 0 -1 0 0 0 0 0 0

68 University of Wisconsin Hospital and Clinics

182 69.6 69.3 63.0 75.7 0 1 1 0 0 0 0 0 0 0

69 Froedtert & Medical College of Wisconsin

238 75.5 67.9 62.2 73.8 -1 -1 -1 0 0 0 0 1 1 1

70 Indiana University Hospital/Riley Hospital for Children

185 64.9 68.7 62.5 75.2 0 0 0 0 0 0 0 0 -1 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

71 Philadelphia Children's Hospital

126 79.2 81.5 75.0 88.0 0 0 0 0 0 0 0 0 0 0

72 Karmanos Cancer Institute 296 63.0 60.8 55.6 66.3 -1 0 0 0 1 1 1 0 0 0

73 Johns Hopkins All Children's Hospital

60 81.6 74.8 64.2 85.3 0 -1 -1 -1 0 0 0 0 0 0

74 University of Nebraska Medical Center

152 72.4 74.6 68.0 81.5 0 0 0 0 0 0 0 0 0 0

75 Children's Hospital of Los Angeles

76 78.9 82.1 73.6 90.3 0 0 0 0 0 -1 -1 0 0 0

76 VA Puget Sound Healthcare System

34 47.1 61.0 44.8 76.4 0 0 0 0 0 0 0 0 0 0

77 Dana Farber Cancer Institute at Brigham and Women's Hospital - Adults

762 73.0 67.3 64.4 70.6 1 1 1 1 0 0 0 1 1 1

78 University of California - San Francisco - Pediatrics

99 85.9 79.4 71.7 87.2 0 0 0 0 1 1 0 0 0 0

79 Vanderbilt University 306 74.4 66.4 61.5 71.5 0 0 0 0 0 0 1 1 1 1

80 City of Hope National Medical Center

789 77.0 69.3 66.4 72.5 1 1 1 1 1 1 1 1 1 1

81 Cincinnati Children's Hospital Medical Center

195 78.9 81.3 76.2 86.7 0 0 0 0 0 0 0 0 0 0

82 H Lee Moffitt Cancer Center 566 69.8 67.2 63.7 71.1 0 0 0 0 0 0 0 0 0 0

83 MD Anderson Cancer Center 1069 63.1 67.1 64.6 70.1 0 0 1 1 0 0 0 0 -1 -1

84 Baylor University Medical Center

337 57.7 59.3 54.5 64.4 0 0 1 0 0 0 0 -1 0 0

85 University of Louisville Hospital/James Brown Cancer Center

61 55.5 65.2 54.1 76.4 -1 0 0 0 0 0 -1 0 -1 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

86 Virginia Commonwealth University Massey Cancer Center BMT Program

186 67.2 71.0 64.8 77.4 0 0 0 0 0 0 0 -1 0 0

87 Oklahoma University Medical Center

106 55.5 62.9 54.4 71.6 0 -1 -1 -1 -1 -1 -1 0 0 0

88 West Penn Hospital 68 52.6 63.2 52.4 73.8 -1 -1 -1 0 0 0 0 0 0 0

89 Children's Hospital of Wisconsin

69 81.2 78.2 69.1 87.3 0 0 0 0 0 0 0 0 0 0

90 Washington University School of Medicine

508 58.8 60.2 56.4 64.4 0 0 0 0 0 0 0 0 -1 0

91 Seidman Cancer Center - University Hospitals Case Medical Center

126 63.3 67.6 59.9 75.5 0 0 0 0 0 0 -1 0 0 0

92 Medical University of South Carolina

143 64.2 65.3 57.9 72.6 0 0 0 0 0 -1 0 -1 0 0

93 Duke University Medical Center; Pediatric BMT

119 69.7 78.5 71.5 85.6 0 0 0 0 1 1 0 0 0 -1

94 University of Rochester Medical Center

152 68.2 67.1 60.1 74.2 0 0 0 0 -1 0 0 0 0 0

95 Yale New Haven Hospital 142 76.8 71.8 64.7 79.0 1 0 0 1 0 0 0 0 1 0

96 Emory University 221 74.6 68.0 62.3 73.9 0 0 0 0 0 0 0 0 0 1

97 Children's National Medical Center

94 78.6 82.8 75.7 90.0 0 0 0 0 0 0 0 -1 0 0

98 Utah Blood and Marrow Transplant Program- Adults

110 68.8 70.4 62.2 78.7 0 0 0 0 0 0 0 0 0 0

99 Cook Children's Medical Center

62 82.3 80.8 71.1 90.0 0 0 0 0 0 0 0 0 0 0

100 Children's Hospital of Orange County

42 66.3 76.4 63.8 88.6 -1 -1 0 0 0 0 0 0 -1 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

101 University of Arkansas for Medical Sciences

2 0.0 53.1 0.0 96.9 -1 -1 -1 -1 -1 -1 -1 -1 -1 0

102 St Jude Children's Research Hospital

157 75.7 75.4 69.1 81.9 0 0 0 0 0 0 0 0 0 0

103 SSM Health Saint Louis University Hospital

48 56.3 64.9 51.4 77.8 0 0 0 0 0 0 0 0 0 0

104 Roswell Park Cancer Institute

197 66.5 65.2 59.0 71.7 0 0 0 1 1 1 1 1 0 0

105 Banner University Medical Center - Tucson

69 65.2 72.0 61.4 82.2 0 0 -1 -1 -1 0 0 0 0 0

106 Wake Forest Baptist Health 95 67.4 67.6 58.5 76.7 0 0 0 0 -1 -1 -1 -1 0 0

107

The Coleman Foundation Blood and Marrow Transplant Center, Rush University

91 72.5 73.2 64.4 82.0 0 0 0 0 0 0 0 0 0 0

108 North Shore University Hospital

83 58.9 72.9 63.6 82.1 0 0 0 0 0 -1 -1 -1 -1 -1

109 Mount Sinai Medical Center - New York

120 55.7 62.1 54.0 70.4 0 -1 -1 -1 -1 -1 0 0 0 0

110 Westchester Medical Center 71 60.8 73.0 63.4 82.6 0 0 -1 0 0 -1 -1 -1 0 -1

111 The University of Michigan 331 74.0 68.1 63.6 73.0 0 0 0 0 0 0 0 0 0 1

112 University of Kansas 321 60.1 66.8 62.1 71.9 0 0 0 0 0 0 0 0 -1 -1

113 Mayo Clinic Rochester 292 75.6 69.5 64.6 74.7 1 1 1 1 0 0 0 0 0 1

114 Tufts New England Medical Center

54 57.4 69.7 58.1 81.0 0 0 0 0 0 0 0 0 0 -1

115 University of Cincinnati Medical Center

5 40.0 70.5 28.5 100.0

-1 0

116 Roger Williams Medical Center

36 72.2 66.1 50.7 80.8

0 -1 0 0 0 0 0 0 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

117 Mayo Clinic Arizona and Phoenix Children's Hospital

302 70.9 71.0 66.3 76.1

1 0 0 0 0 1 1 0 0

118 Dartmouth-Hitchcock Medical Center

61 67.2 70.7 59.4 81.9

0 0 0 1 0 -1 -1 -1 0

119 The Children's Mercy Hospitals and Clinics

57 75.4 79.7 69.6 89.7

0 0 0 0 0 0 0 0

120 Wilford Hall Medical Center 29 79.2 76.5 61.3 90.7

0 0 0 0 0 0 0

121 Via Christi Hospitals Wichita 11 54.5 70.9 42.3 95.1

0 0 0 0 0 0 0

122 Sutter Cancer Center 74 60.8 68.9 58.8 78.9

0 0 0 -1 -1 -1 0

123 Massachusetts General Hospital

249 76.5 72.4 67.1 78.0

0 1 0 1 0 1 0

124 National Heart Lung & Blood Institute

81 88.6 80.1 71.8 88.3

0 0 0 0 1

125 New York Presbyterian Hospital/Columbia University Medical Center

20 35.0 69.2 49.6 87.7

0 -1

126 Montefiore Medical Center 77 56.8 64.9 54.8 75.0

-1 -1 -1 0 -1 -1 0

127 Advocate Lutheran General Hospital

11 81.8 71.3 44.0 94.9

0 0 0 0 0 0 0

128 State University of NY Upstate Medical University

1 100.0 73.8 0.0 100.0

0 0 0

129 USC BMT Program 66 80.2 74.4 64.2 84.4

-1 0 0 0

130 GHS Cancer Institute 2 100.0 80.4 16.9 100.0

0 0 0 0 0 0 0

131 New York University Medical Center

8 85.7 75.4 44.2 100.0

0 0 0

132 Stony Brook University Hospital

45 64.4 71.5 58.9 83.6

0 0 0 -1 0 0 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

133 Blood & Marrow Transplant Center, Florida Hospital Medical Group

133 75.1 66.4 58.6 74.2

0 0 0 0 0 1 1

134 Georgia Cancer Center at Augusta University Health

48 45.8 67.2 54.2 79.7

0 0 0 0 0 -1

135 Geisinger Medical Center 6 83.3 76.2 39.7 100.0

0 0 0 0 0 0 0

136 Saint Francis Hospital -Oklahoma

3 33.3 57.9 0.0 97.8

0 0 0 0 0 0 0

137 Northwestern University-Dept of Immunotherapy

9 72.9 69.6 38.3 97.4 0 0 0

0 0 0 0 0

138 National Institutes of Health 7 71.4 71.1 37.0 99.6

0 0 0 0 0 0 0 0

139 Cancer Treatment Centers of America - Midwestern Regional Medical Center

42 45.2 64.0 49.7 77.3

-1 0 0 0 -1 -1 -1

140 Akron Children's Hospital 18 66.7 76.3 56.3 94.2

0 0 0 0 0 0 0

141 Sarah Cannon BMT Center at Centennial Medical Center

45 46.7 67.9 54.8 80.6

0 0 0 0 0 -1 -1

142 St Christopher's Hospital for Children

2 50.0 89.3 42.5 100.0

0 0

143 Pediatric BMT Program, Doernbecher Children's Hospital (OHSU)

41 77.7 76.5 63.6 88.6 0 0 0 0 0 0 0 0 0 0

144 Children's Hospital of Pittsburgh of UPMC

60 79.8 80.4 70.6 90.2

0 0 0 0 0 0

145 Dana Farber Cancer Institute & Boston Children's Hospital

169 83.5 81.6 76.1 87.4 1 1 1 0 0 0 0 0 0 0

146 University of California - San Francisco - Adults

181 70.5 68.5 62.2 75.0 0 0 0 1 1 1 0 0 0 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

147 Washington University/St Louis Children's Hospital

64 78.1 82.3 73.3 91.2 0 0 0 0 0 0 0 0 -1 0

148 Duke University - Adults 251 61.1 63.1 57.6 69.0 0 0 0 0 -1 -1 0 0 0 0

149 University of Colorado Hospital

131 72.2 59.0 51.0 67.2

0 0 0 1 1 1 1

150 University of Chicago Medical Center

193 59.6 67.5 61.6 73.9 0 0 0

0 -1 -1 -1 0 -1

151 National Institutes of Allergy & Infectious Disease

3 100.0 85.2 40.0 100.0

0 0

0 0

152 UCLA Center for Health Sciences

220 61.6 70.8 65.2 76.8 -1 -1 -1 -1 0 0 0 0 -1 -1

153 NIH - NCI Matched Unrelated Donor Program

63 80.9 73.4 63.1 83.5

0 0 0 0 0 0 0 0

154 Children's Hospital of Michigan

29 75.7 81.0 67.0 94.2

0 0 0 0 0 0 -1 0

155 Vanderbilt University Veterans Center

85 77.6 66.7 57.1 76.2 0 0 0 0

0 0 0 0 1

156 University of Miami/Jackson Memorial Hospital

43 71.6 76.8 64.5 88.6 0 0 0 0 0 0 0 0 0 0

157 Duke University, Immunology/BMT, Pediatrics

7 100.0 84.3 55.3 100.0 0 0 0

0 0 0 0 0 0

158 BMT Program at Levine Children's Hospital / Carolinas Medical Center

42 76.2 79.5 67.6 91.1

0 0 0 0 0 0 0

159 Memorial Cancer Institute 4 75.0 72.4 25.6 100.0

0 0

160 Utah Blood and Marrow Transplant Program-Pediatrics

54 68.4 76.9 66.0 87.8 0 0 0 0 0 0 1 0 0 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

161 Saint Francis Hospital- Greenville

1 0.0 74.0 0.0 100.0

0 0 0 0 0

162 Memorial Sloan Kettering Cancer Center - Adults

496 73.5 65.6 61.8 69.7 1 1 1

1 1 1 1 1 1

163 Memorial Sloan Kettering Cancer Center - Pediatrics

106 79.2 74.0 66.4 81.7 1 1 1 1 0 0 0 0 1 0

164 Ochsner Medical Center 13 92.3 71.7 46.6 94.0

0 0

165 University of Virginia Health System

35 62.6 64.0 48.8 78.7

0 0 0

166 Cancer Transplant Institute at Virginia G. Piper Cancer Center

101 71.2 68.5 60.1 77.2

0 0 0

167 Baptist Blood and Marrow Transplant

15 60.0 76.3 54.6 95.9 0 0 0 0 0 -1 0 -1 0 0

168 Kapi'olani Medical Center for Women and Children

7 42.9 83.1 53.9 100.0

0 0 -1 -1

169 Banner MD Anderson Cancer Center

3 66.7 67.9 7.0 100.0

0

170 Spectrum Health 35 65.7 67.2 51.9 81.4

0 0

171 Cancer Treatment Centers of America-Tulsa, OK

2 50.0 82.6 24.4 100.0

0

172 South Texas Veterans Health Care System

6 66.7 77.9 42.8 100.0

0 0

173 Eastern Regional Medical Center

1 100.0 75.6 0.0 100.0 0

174 Childrens Hospital at Montefiore

8 87.5 82.9 55.0 100.0 0 0 0


Table 3. Continued.



Actual (%)

Predicted (%)

Lower (%)

Upper (%) ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16

175 Lucile Packard Children's Hospital4

78 84.5 79.1 70.5 87.7 0 0 0 0 0 0 0 0 0 0

176 Stanford University Medical Center4

499 72.0 70.6 67.0 74.7 0 0 0 0 0 0 0 0 0 0

177 Levine Cancer Institute 15 79.4 65.4 40.4 87.7 0

178

University of Minnesota Blood and Marrow Transplant Program- Pediatrics

179 77.5 78.2 72.5 84.3 0 0 0 0 0 0 0 0 -1 0

179 University of Minnesota Blood and Marrow Transplant Program- Adults

295 62.8 68.9 64.0 74.1 0 0 0 0 0 0 0 0 -1 -1

1 -1 indicates under-performing; 1 indicates over-performing; 0 indicates performing as predicted. 2 Report year 2006 includes 2000-2004; 2007 includes 2001-2005; 2008 includes 2002-2006; 2009 includes 2003-2007; 2010 includes unrelated HCTs performed in 2004-2008 and

related HCTs performed in 2008; 2011 includes unrelated HCTs performed in 2007-2009 and related HCTs performed in 2008-2009; 2012 includes unrelated and related HCTs performed in 2008-2010; 2013 includes unrelated and related HCTs performed in 2009-2011; 2014 includes unrelated and related HCTs performed in 2010-2012; 2015 includes unrelated and related HCTs performed in 2011-2013; 2016 includes unrelated and related HCTs performed in 2012-2014.

3 University of Tennessee BMT Program merged with Baptist Center for Cancer Care to become Baptist Blood and Marrow Transplant program as of February 2012. Results in the 2014 and 2015 column represent those of the combined program. Results in the 2007-2013 columns are those of the University of Tennessee program alone.

4 Stanford University Medical Center split into Stanford University Medical Center (adult program) and Lucile Packard Children's Hospital (pediatric program) as of September 2015. The results for report years 2007-2015 are for the combined program.


Table 4. Summary Results for Analyses from 2006-2016

Report Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Years of HCT included 2000-2004*

2001-2005*

2002-2006*

2003-2007*

2004-2008 (Unrelated)

2008 (Related)

2007-2009 (Unrelated) 2008-2009 (Related)

2008-2010

2009-2011

2010-2012

2011-2013

2012-2014

Total number of centers 112 119 122 125 153 156 168 168 167 173 179

Number of centers below predicted lower confidence limit (under-performing)

13 (12) 12 (10) 11 (9) 14 (11) 12 (8) 20 (13) 26 (15) 22 (13) 24 (14) 27 (16) 23 (13)

Number of centers above predicted upper confidence limit (over-performing)

2 (2) 7 (6) 8 (7) 9 (7) 11 (7) 14 (9) 10 (6) 13 (8) 15 (9) 17 (10) 17 (9)

*Unrelated HCT only


Table 5. Summary of under-performing or over-performing centers across 2007-2016 analyses

Center Performance by Report Year1,2

Code Center Name 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

3 Avera Mckennan Transplant Institute 0 0 0 0 -1 -1 -1 -1 -1 -1

5 Loma Linda University Cancer Center 1 1 1 1 0 0 0 0 0 0

6 Mayo Clinic Florida - Jacksonville 0 0 0 0 0 0 -1 -1

7 BMT Program of Mayo Clinic/ Nemours and Wolfson Children's Hospital

0 0 -1 -1 0 0 0 0

10 University of North Carolina Hospitals - Chapel Hill 0 0 0 0 1 0 0 0 0 0

12 University of Alabama Birmingham 0 0 0 0 0 0 0 -1 -1 -1

14 Ann & Robert H. Lurie Children's Hospital of Chicago 0 0 0 0 1 0 0 0 0 0

15 Christiana Care -1 -1 0 0 0 0 0 0 0 0

17 Temple Bone Marrow Transplant Program 0 0 0 0 -1 0 -1 0 0 0

18 Texas Transplant Institute 0 0 0 0 0 0 0 0 -1 0

19 Children's Medical Center - Dallas -1 -1 -1 0 0 0 0 -1 -1 -1

22 Loyola University Medical Center

0 -1 0 0 0 0

23 The Children's Hospital of Denver 0 0 0 1 1 1 0 0 0 0

25 Baylor College of Medicine 0 0 0 0 0 0 1 1 0 1

27 University of Maryland School of Medicine 0 0 -1 -1 0 0 0 0 0 0

29 University of Mississippi Medical Center - Jackson -1 0 0 0 -1 -1 0 -1 -1 -1

32 Thomas Jefferson University -1 -1 -1 -1 0 0 0 0 0 0

33 Abramson Cancer Center University - Pennsylvania Medical Center

0 0 0

-1 -1 -1 1 1 1

34 Children's Healthcare of Atlanta at Egleston 0 0 0 0 0 0 0 1 1 0

37 The Blood and Marrow Transplant Program at Northside Hospital

0 0 1 1 1 1 1 1 1 1

39 Miami Children's Hospital 0 0 0 0 0 -1 0 0 0 0

40 Louisiana State University Children's Hospital 0 0 0 0 0 0 -1 -1 0 -1

41 Penn State Hershey Medical Center 0 0 0 0 0 -1 -1 -1 -1 -1

43 Northwestern Memorial Hospital 0 0 0 . . -1 0 0 0 0

45 Tulane University Medical Center 0 0 0 0 -1 0 0 0 0 0


Table 5. Continued. Center Performance by Report Year1,2

Code Center Name 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

47 Beth Israel Deaconess Medical Center 0 0 0 0 0 0 0 0 1 0

50 Cedars Sinai Medical Center 0 0 -1 -1 -1 -1 -1 -1 -1 -1

52 Children's Hospital of Oakland 0 0 0 0 0 -1 0 0 0 0

53 Fairfax-Northern Virginia Hospital 0 0 0 0 -1 -1 -1 -1 -1 -1

56 Texas Tech University Medical Center 0 0 0 0 0 0 -1 -1 0 0

58 Charleston Hematology Oncology

0 -1 -1 0 0 0 0

59 Fred Hutchinson Cancer Center 1 1 0 0 0 0 1 1 1 1

60 Shands HealthCare & University of Florida 0 0 0 0 -1 0 0 1 1 0

61 University of Iowa Hospital & Clinics 0 0 0 0 -1 0 0 1 1 1

63 Johns Hopkins Oncology Center 0 0 0

1 1 1 0 0 0

64 Cleveland Clinic 0 0 0 0 0 0 0 -1 0 0

67 University of Pittsburgh Medical Center 0 0 0 -1 0 0 0 0 0 0

68 University of Wisconsin Hospital and Clinics 0 1 1 0 0 0 0 0 0 0

69 Froedtert & Medical College of Wisconsin -1 -1 -1 0 0 0 0 1 1 1

70 Indiana University Hospital/Riley Hospital for Children 0 0 0 0 0 0 0 0 -1 0

72 Karmanos Cancer Institute -1 0 0 0 1 1 1 0 0 0

73 All Children's Hospital 0 -1 -1 -1 0 0 0 0 0 0

75 Children's Hospital of Los Angeles 0 0 0 0 0 -1 -1 0 0 0

77 Dana Farber Cancer Institute at Brigham and Women's Hospital - Adults

1 1 1 1 0 0 0 1 1 1

78 University of California - San Francisco - Pediatrics 0 0 0 0 1 1 0 0 0 0

79 Vanderbilt University 0 0 0 0 0 0 1 1 1 1

80 City of Hope National Medical Center 1 1 1 1 1 1 1 1 1 1

83 MD Anderson Cancer Center 0 0 1 1 0 0 0 0 -1 -1

84 Baylor University Medical Center 0 0 1 0 0 0 0 -1 0 0

85 University of Louisville Hospital/James Brown Cancer Center

-1 0 0 0 0 0 -1 0 -1 0

86 Virginia Commonwealth University Massey Cancer Center BMT Program

0 0 0 0 0 0 0 -1 0 0

87 Oklahoma University Medical Center 0 -1 -1 -1 -1 -1 -1 0 0 0



Code Center Name 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

88 West Penn Hospital -1 -1 -1 0 0 0 0 0 0 0

90 Washington University School of Medicine 0 0 0 0 0 0 0 0 -1 0

91 Seidman Cancer Center - University Hospitals Case Medical Center

0 0 0 0 0 0 -1 0 0 0

92 Medical University of South Carolina 0 0 0 0 0 -1 0 -1 0 0

93 Duke University Medical Center; Pediatric BMT 0 0 0 0 1 1 0 0 0 -1

94 University of Rochester Medical Center 0 0 0 0 -1 0 0 0 0 0

95 Yale New Haven Hospital 1 0 0 1 0 0 0 0 1 0

96 Emory University 0 0 0 0 0 0 0 0 0 1

97 Children's National Medical Center 0 0 0 0 0 0 0 -1 0 0

100 Children's Hospital of Orange County -1 -1 0 0 0 0 0 0 -1 0

101 University of Arkansas for Medical Sciences -1 -1 -1 -1 -1 -1 -1 -1 -1 0

104 Roswell Park Cancer Institute 0 0 0 1 1 1 1 1 0 0

105 Banner University Medical Center - Tucson 0 0 -1 -1 -1 0 0 0 0 0

106 Wake Forest Baptist Health 0 0 0 0 -1 -1 -1 -1 0 0

108 North Shore University Hospital 0 0 0 0 0 -1 -1 -1 -1 -1

109 Mount Sinai Medical Center - New York 0 -1 -1 -1 -1 -1 0 0 0 0

110 Westchester Medical Center 0 0 -1 0 0 -1 -1 -1 0 -1

111 The University of Michigan 0 0 0 0 0 0 0 0 0 1

112 University of Kansas 0 0 0 0 0 0 0 0 -1 -1

113 Mayo Clinic Rochester 1 1 1 1 0 0 0 0 0 1

114 Tufts New England Medical Center 0 0 0 0 0 0 0 0 0 -1

115 University of Cincinnati Medical Center -1 0

116 Roger Williams Medical Center 0 -1 0 0 0 0 0 0 0

117 Mayo Clinic Arizona and Phoenix Children's Hospital 1 0 0 0 0 1 1 0 0

118 Dartmouth-Hitchcock Medical Center

0 0 0 1 0 -1 -1 -1 0

122 Sutter Cancer Center

0 0 0 -1 -1 -1 0

123 Massachusetts General Hospital

0 1 0 1 0 1 0

124 National Heart Lung & Blood Institute

0 0 0 0 1



Code Center Name 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

125 New York Presbyterian Hospital/Columbia University Medical Center

0 -1

126 Montefiore Medical Center -1 -1 -1 0 -1 -1 0

129 USC BMT Program

-1 0 0 0

132 Stony Brook University Medical Center

0 0 0 -1 0 0 0

133 Blood & Marrow Transplant Center, Florida Hospital Medical Group

0 0 0 0 0 1 1

134 Georgia Cancer Center at Augusta University Health 0 0 0 0 0 -1

139 Cancer Treatment Centers of America - Midwest

-1 0 0 0 -1 -1 -1

141 Sarah Cannon BMT Center at Centennial Medical Center 0 0 0 0 0 -1 -1

145 Dana Farber Cancer Institute at Brigham and Women's Hospital-Pediatrics

1 1 1 0 0 0 0 0 0 0

146 University of California - San Francisco - Adults 0 0 0 1 1 1 0 0 0 0

147 Washington University/St Louis Children's Hospital 0 0 0 0 0 0 0 0 -1 0

148 Duke University - Adults 0 0 0 0 -1 -1 0 0 0 0

149 University of Colorado Hospital 0 0 0 1 1 1 1

150 University of Chicago Medical Center 0 0 0 0 -1 -1 -1 0 -1

152 UCLA Center for Health Sciences -1 -1 -1 -1 0 0 0 0 -1 -1

154 Children's Hospital of Michigan 0 0 0 0 0 0 -1 0

155 Vanderbilt University Veterans Center 0 0 0 0 . 0 0 0 0 1

160 Utah Blood and Marrow Transplant Program-Pediatrics 0 0 0 0 0 0 1 0 0 0

162 Memorial Sloan Kettering Cancer Center - Adults 1 1 1 1 1 1 1 1 1

163 Memorial Sloan Kettering Cancer Center - Pediatrics 1 1 1 1 0 0 0 0 1 0

167 Baptist Blood and Marrow Transplant3 0 0 0 0 0 -1 0 -1 0 0

168 Kapi'olani Medical Center for Women and Children 0 0 -1 -1

178 University of Minnesota Blood and Marrow Transplant Program- Pediatrics

0 0 0 0 0 0 0 0 -1 0

179 University of Minnesota Blood and Marrow Transplant Program- Adults

0 0 0 0 0 0 0 0 -1 -1

1 –1 indicates under-performing; 1 indicates over-performing; 0 indicates performing as predicted.


2 Report year 2006 includes 2000-2004; 2007 includes 2001-2005; 2008 includes 2002-2006; 2009 includes 2003-2007; 2010 includes unrelated HCTs performed in 2004-2008 and related HCTs performed in 2008; 2011 includes unrelated HCTs performed in 2007-2009 and related HCTs performed in 2008-2009; 2012 includes unrelated and related HCTs performed in 2008-2010; 2013 includes unrelated and related HCTs performed in 2009-2011; 2014 includes unrelated and related HCTs performed in 2010-2012; 2015 includes unrelated and related HCTs performed in 2011-2013; 2016 includes unrelated and related HCTs performed in 2012-2014 3 University of Tennessee BMT Program merged with Baptist Center for Cancer Care to become Baptist Blood and Marrow Transplant program as of February 2012. Results in the 2014 and 2015 column represent those of the combined program. Results in the 2007-2013 columns are those of the University of Tennessee program alone.


Table 6. Probability (unadjusted) of survival at one year after first allogeneic HCT for patients transplanted in the United States from unrelated or related donors between 2012 and 2014

2012 2013 2014 2012-2014

N Prob (95 CI) N Prob (95 CI) N Prob (95 CI) N Prob (95 CI)

Unrelated donor HCT 4248 65 (64-67) 4675 67 (66-68) 4601 66 (65-68) 13055 66 (65-67) Related donor HCT 3036 73 (72-75) 3182 72 (70-73) 3262 73 (71-74) 9119 72 (72-73)


Figure 1a. Center-Specific Results

Box indicates predicted survival with 95 confidence interval. Dashed line indicates overall network survival rate of 68.9.

Dot indicates a center’s actual survival; a dot below (above) the box indicates an under (over)-performing center relative to the network.

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

21 56 66 101 115 128 130 135 136 142 151 159 161 169 171 172 173

Su

rviv

al

Transplant Center Code

Predicted and Actual Survival Rates for Transplant Centers with1 - 6 Transplants


Figure 1b. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

7 31 42 53 58 121 125 127 131 137 138 140 157 164 167 168 174 177

Su

rviv

al




Figure 1c. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

3 5 15 39 40 45 52 54 55 57 76 100 116 120 139 143 154 158 165 170

Su

rviv

al




Figure 1d. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

1 51 73 85 99 103 114 118 119 132 134 141 144 147 153 156 160

Su

rviv

al




Figure 1e. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

4 8 14 17 19 23 29 35 36 38 46 75 88 89 105 110 122 129

Su

rviv

al




Figure 1f. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

2 6 11 28 34 44 47 62 78 97 106 107 108 124 126 155 166 175

Su

rviv

al




Figure 1g. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

20 26 27 32 48 50 60 67 71 87 91 93 98 109 133 149 163

Su

rviv

al




Figure 1h. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

9 10 22 30 61 68 70 74 81 86 92 94 95 102 145 146 150 178

Su

rviv

al




Figure 1i. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

12 13 18 24 25 33 37 41 43 49 64 69 72 96 104 113 123 148 152 179

Su

rviv

al


Predicted and Actual Survival Rates for Transplant Centers with196-299 Transplants


Figure 1j. Center-Specific Results



0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

16 59 63 65 77 79 80 82 83 84 90 111 112 117 162 176

Su

rviv

al


Predicted and Actual Survival Rates for Transplant Centers withOver 299 Transplants

Final Transplant Center-Specific Survival Report · Final 2016 Transplant Center-Specific Survival...

Documents

Transcript of Final Transplant Center-Specific Survival Report · Final 2016 Transplant Center-Specific Survival...